1. [Genetic architecture of amyotrophic lateral sclerosis and frontotemporal dementia : Overlap and differences]
- Author
-
Synofzik, M., Otto, M., Ludolph, A., and Weishaupt, J. H.
- Subjects
methods [High-Throughput Nucleotide Sequencing] ,therapy [Frontotemporal Dementia] ,DNA Mutational Analysis ,genetics [DNA-Binding Proteins] ,MAPT protein, human ,tau Proteins ,Comorbidity ,genetics [Gene Expression Regulation] ,Progranulins ,Superoxide Dismutase-1 ,Humans ,therapy [Amyotrophic Lateral Sclerosis] ,ddc:610 ,Molecular Targeted Therapy ,genetics [C9orf72 Protein] ,genetics [Frontotemporal Dementia] ,Genetic Association Studies ,C9orf72 Protein ,genetics [Intercellular Signaling Peptides and Proteins] ,TDP-43 protein, human ,Amyotrophic Lateral Sclerosis ,SOD1 protein, human ,High-Throughput Nucleotide Sequencing ,FUS protein, human ,genetics [Superoxide Dismutase-1] ,DNA-Binding Proteins ,genetics [Amyotrophic Lateral Sclerosis] ,genetics [tau Proteins] ,Phenotype ,Gene Expression Regulation ,Frontotemporal Dementia ,GRN protein, human ,Intercellular Signaling Peptides and Proteins ,RNA-Binding Protein FUS ,C9orf72 protein, human ,genetics [RNA-Binding Protein FUS] - Abstract
Amyotrophic lateral sclerosis (ALS) and frontotemporal dementia (FTD) overlap not only clinically, but also with respect to shared neuropathology and genes. A large number of novel genes has recently been identified which underlie both diseases, e. g., C9orf72, TARDBP, GRN, TBK1, UBQLN2, VCP, CHCHD10, or SQSTM1. In contrast, other genes are still largely associated with only one of the two diseases, e. g., SOD1 with ALS or MAPT with FTD. These genetic findings indicate a large number of shared mechanisms, yet along with still a certain cell-specific vulnerability. The recently identified genes are not only key to investigate the pathophysiology underlying ALS and FTD, but also the first step in the development of causal gene- or pathway-specific therapies. Mutations in these genes are also found in a substantial share of seemingly 'sporadic' ALS and FTD patients. Given the large genetic heterogeneity with more than >25 genes having been identified for ALS and FTD, genetic diagnostics should - after exclusion of C9orf72 repeat expansions - no longer resort to single gene-diagnostics, but rather use next generation sequencing panels or whole exome sequencing.
- Published
- 2017
- Full Text
- View/download PDF